CONTEXT: Maturity onset diabetes of the young (MODY) type 5 has been described as the association of early-onset diabetes and renal disease. Actually, MODY5 encompasses multiple phenotypes, including nondiabetic progressive renal failure, kidney and genital tract malformations, atypical familial hyperuricemic nephropathy, pancreas atrophy, and liver test abnormalities. The occurrence of MODY5 has been associated with various molecular abnormalities of TCF2, including missense, nonsense, small insertion/deletions, and splice site mutations, as well as large genomic deletions or single exonic deletion of TCF2. DESIGN: Using quantitative multiplex PCR amplification of short fluorescent fragments, we have analyzed the TCF2 gene in a French family of which three relatives presented a MODY5 phenotype. The proband had an extended clinical phenotype, including hyperuricemic nephropathy and early gout, chronic renal failure, renal morphological abnormalities, abnormal liver tests, and diabetes. His son had almost no clinical expression of the disease, whereas his grandson had a restricted but severe renal phenotype present from birth. RESULTS: We show that a duplication of the exon 5 of TCF2 is responsible for the MODY5 phenotypes in this family. CONCLUSIONS: Thus, we describe a novel molecular mechanism that may be responsible for MODY5, and we emphasize the wide intrafamilial variability of MODY5 expressivity. These observations suggest that the diagnosis of MODY5 may be raised even in subjects with partial phenotypes. They also confirm that quantitative multiplex PCR amplification of short fluorescent fragments analysis should be the first step of genetic screening in patients with a MODY5 phenotype.
CONTEXT: Maturity onset diabetes of the young (MODY) type 5 has been described as the association of early-onset diabetes and renal disease. Actually, MODY5 encompasses multiple phenotypes, including nondiabetic progressive renal failure, kidney and genital tract malformations, atypical familial hyperuricemic nephropathy, pancreas atrophy, and liver test abnormalities. The occurrence of MODY5 has been associated with various molecular abnormalities of TCF2, including missense, nonsense, small insertion/deletions, and splice site mutations, as well as large genomic deletions or single exonic deletion of TCF2. DESIGN: Using quantitative multiplex PCR amplification of short fluorescent fragments, we have analyzed the TCF2 gene in a French family of which three relatives presented a MODY5 phenotype. The proband had an extended clinical phenotype, including hyperuricemic nephropathy and early gout, chronic renal failure, renal morphological abnormalities, abnormal liver tests, and diabetes. His son had almost no clinical expression of the disease, whereas his grandson had a restricted but severe renal phenotype present from birth. RESULTS: We show that a duplication of the exon 5 of TCF2 is responsible for the MODY5 phenotypes in this family. CONCLUSIONS: Thus, we describe a novel molecular mechanism that may be responsible for MODY5, and we emphasize the wide intrafamilial variability of MODY5 expressivity. These observations suggest that the diagnosis of MODY5 may be raised even in subjects with partial phenotypes. They also confirm that quantitative multiplex PCR amplification of short fluorescent fragments analysis should be the first step of genetic screening in patients with a MODY5 phenotype.
Authors: Donghui Li; Eric J Duell; Kai Yu; Harvey A Risch; Sara H Olson; Charles Kooperberg; Brian M Wolpin; Li Jiao; Xiaoqun Dong; Bill Wheeler; Alan A Arslan; H Bas Bueno-de-Mesquita; Charles S Fuchs; Steven Gallinger; Myron Gross; Patricia Hartge; Robert N Hoover; Elizabeth A Holly; Eric J Jacobs; Alison P Klein; Andrea LaCroix; Margaret T Mandelson; Gloria Petersen; Wei Zheng; Ilir Agalliu; Demetrius Albanes; Marie-Christine Boutron-Ruault; Paige M Bracci; Julie E Buring; Federico Canzian; Kenneth Chang; Stephen J Chanock; Michelle Cotterchio; J Michael Gaziano; Edward L Giovannucci; Michael Goggins; Göran Hallmans; Susan E Hankinson; Judith A Hoffman Bolton; David J Hunter; Amy Hutchinson; Kevin B Jacobs; Mazda Jenab; Kay-Tee Khaw; Peter Kraft; Vittorio Krogh; Robert C Kurtz; Robert R McWilliams; Julie B Mendelsohn; Alpa V Patel; Kari G Rabe; Elio Riboli; Xiao-Ou Shu; Anne Tjønneland; Geoffrey S Tobias; Dimitrios Trichopoulos; Jarmo Virtamo; Kala Visvanathan; Joanne Watters; Herbert Yu; Anne Zeleniuch-Jacquotte; Laufey Amundadottir; Rachael Z Stolzenberg-Solomon Journal: Carcinogenesis Date: 2012-04-20 Impact factor: 4.944